Topical Tranexamic Acid for Bilateral Breast Reduction Surgery

Status Not yet recruiting

Clinical Trial Summary

Hematoma is a common complication of bilateral breast reduction (BBR) surgery. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events. In this randomized control trial (RCT) evaluation TXA use in BBR, for which one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in BBR reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.

Clinical Trial Description

The primary objective of this study is to investigate the use of topical application of tranexamic Acid (TXA) to the surgical wound as a means to decrease hematoma formation compared to placebo in patients undergoing bilateral breast reduction (BBR). This project is designed as a single-center RCT to evaluate the effectiveness of topical TXA in this patient population. If enrolled in this study, patients individual breasts will be randomly assigned to one of two treatment groups for to apply to the wound before it is closed. One breast will have an intravenous form of TXA applied topically to the surgical site. The other will be have a topical normal saline solution applied to the wound before closure (a placebo). The patients will have the standard number of drains and postoperative instructions for breast reduction. They will follow-up at two weeks time in clinic for assessment, and emergency room visits will be also be evaluated. Standard of care will be practiced with respect to all procedures and visits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04918576
Study type	Interventional
Source	McMaster University
Contact	Yaeesh Sardiwalla, MD
Phone	90505221155
Email	yaeesh.sardiwalla@medportal.ca
Status	Not yet recruiting
Phase	Phase 3
Start date	August 2022
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06280456` - Tranexamic Acid Injection With Different Drainage Clamping Time After Anterior Cruciate Ligament Reconstruction	N/A
Recruiting	`NCT06067217` - Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users	N/A
Completed	`NCT03113253` - TRANexamic Acid to Reduce Bleeding in BURN Surgery	Phase 4
Completed	`NCT02903017` - Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage	Phase 4
Completed	`NCT02569658` - Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty	N/A
Completed	`NCT04911413` - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery	Phase 4
Terminated	`NCT03085394` - Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery	Phase 3
Recruiting	`NCT02938962` - Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)	Phase 4
Completed	`NCT01895101` - The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients	Phase 4
Completed	`NCT02806024` - Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study	Phase 4
Completed	`NCT03897621` - The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery	N/A
Completed	`NCT03360045` - Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis	Phase 4
Completed	`NCT06301204` - Effectiveness Of Tranexamic Acıd Application Wıth Different Doses On Bleeding, Edema And Physician Comfort In Orthognathıc Surgery Patients	N/A
Completed	`NCT04025736` - Arthroscopic Shoulder Surgery With Administration of Intravenous Tranexamic Acid	N/A
Completed	`NCT04427618` - Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section	Phase 3
Not yet recruiting	`NCT05913466` - Intraprostatic Injection of Tranexamic Acid Decrease Blood Loss During Monopolar TURP	N/A
Recruiting	`NCT05230381` - Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection	N/A
Completed	`NCT01980355` - TXA Study in Major Oncologic Surgery	N/A
Not yet recruiting	`NCT06010368` - Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section	Phase 3
Withdrawn	`NCT03433144` - The Effects of Tranexamic Acid on Blood Loss During Orthognathic Surgery	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.